Plain-English translation of NCT06017362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether topical 1UI/ml eye drops can help treat dry eye disease in people who are already using glaucoma medications. Some participants will receive the drops four times daily, while others will receive artificial tears (a placebo) four times daily. The study aims to see if this medication is both safe and effective for people managing both dry eye and glaucoma at the same time.
Dry eye is a common side effect for people taking long-term glaucoma medications, and current treatments don't always work well enough. This trial exists to see whether this medication could offer a new option for patients dealing with both conditions.
You likely qualify if…
You likely don't qualify if…
You will be recruited through an ophthalmology clinic in Madrid and assigned to receive either eye drops or artificial tears, four times daily. Throughout the study, you will visit the clinic for scheduled appointments where doctors will examine your eyes, assess your symptoms, and monitor your safety. The study will continue for a set period while you use your assigned treatment alongside your regular glaucoma medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Spain